| Cristin Samantha Hagelstein, MD | |
|
154 Exton Square Mall, Nemours Dupont Pediatrics, Exton, Exton, PA 19341-2440 | |
| (484) 565-8507 | |
| (610) 280-1531 |
| Full Name | Cristin Samantha Hagelstein |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Location | 154 Exton Square Mall, Exton, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063646131 | NPI | - | NPPES |
| 23-2359401 | Other | PA | MAIN LINE HEALTHCARE TAX ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD446432 (Pennsylvania) | Secondary |
| 208D00000X | General Practice | MD446432 (Pennsylvania) | Primary |
| Entity Name | The Nemours Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902959653 PECOS PAC ID: 9537072483 Enrollment ID: O20040204000144 |
News Archive
A new study published on the medRxiv* preprint server presents a standardized survey instrument for evaluating risk factors associated with bidirectional zoonotic transmission of SARS-CoV-2 and pathogens. The instrument is particularly focused on settings where humans and animals share close contact.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will introduce the new DC-T6 ultrasound system at the annual Radiological Society of North America conference.
MEDNAX, Inc., the national medical group specializing in neonatal, anesthesia, maternal-fetal, pediatric cardiology and other pediatric subspecialty physician services, today reported earnings of $0.78 per share for the three months ended December 31, 2013. MEDNAX's earnings per share data reflect the impact of a two-for-one stock split that was effective December 19, 2013.
› Verified 1 days ago
| Entity Name | Childrens Health Care Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598869059 PECOS PAC ID: 1355253527 Enrollment ID: O20040216001108 |
News Archive
A new study published on the medRxiv* preprint server presents a standardized survey instrument for evaluating risk factors associated with bidirectional zoonotic transmission of SARS-CoV-2 and pathogens. The instrument is particularly focused on settings where humans and animals share close contact.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will introduce the new DC-T6 ultrasound system at the annual Radiological Society of North America conference.
MEDNAX, Inc., the national medical group specializing in neonatal, anesthesia, maternal-fetal, pediatric cardiology and other pediatric subspecialty physician services, today reported earnings of $0.78 per share for the three months ended December 31, 2013. MEDNAX's earnings per share data reflect the impact of a two-for-one stock split that was effective December 19, 2013.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cristin Samantha Hagelstein, MD Po Box 191, Provider Enrollment Department, Rockland, DE 19732-0191 Ph: (302) 651-6212 | Cristin Samantha Hagelstein, MD 154 Exton Square Mall, Nemours Dupont Pediatrics, Exton, Exton, PA 19341-2440 Ph: (484) 565-8507 |
News Archive
A new study published on the medRxiv* preprint server presents a standardized survey instrument for evaluating risk factors associated with bidirectional zoonotic transmission of SARS-CoV-2 and pathogens. The instrument is particularly focused on settings where humans and animals share close contact.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will introduce the new DC-T6 ultrasound system at the annual Radiological Society of North America conference.
MEDNAX, Inc., the national medical group specializing in neonatal, anesthesia, maternal-fetal, pediatric cardiology and other pediatric subspecialty physician services, today reported earnings of $0.78 per share for the three months ended December 31, 2013. MEDNAX's earnings per share data reflect the impact of a two-for-one stock split that was effective December 19, 2013.
› Verified 1 days ago
James Lewis, DO General Practice Medicare: Not Enrolled in Medicare Practice Location: 102 Pickering Way, Suite 200, Exton, PA 19341 Phone: 215-738-2954 Fax: 484-341-8184 |